Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jim Plante
AddedMar 31, 2024
UpdatedMay 31, 2026
Jim Plante

Jim Plante

Founder, Thynk Capital

CrunchbaseLinkedIn

Jim Plante's Career

Thynk Capital
Thynk Capital

Las Vegas, NV, US

Founder
Klotho Therapeutics
Klotho Therapeutics

San Diego, CA, US

Board Member· Board
IMX
IMX

Chicago, IL, US

Founder & CEO· C-Suite · Management
Pathway Genomics
Pathway Genomics

San Diego, CA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jim Plante's Career

Thynk Capital
Thynk Capital
Investment Firm32016Las Vegas, NV, US
Founder
Klotho Therapeutics
Klotho Therapeutics
Series A$10M22016San Diego, CA, US
Board Member· Board
IMX
IMX
Investment Firm$5.1M52021Chicago, IL, US
Founder & CEO· C-Suite · Management
Pathway Genomics
Pathway Genomics
Series E$43M1752008San Diego, CA, US
Founder

Leadership at Pathway Genomics

Peter PacePeter PaceBoard Member
VADIM SHULMANVADIM SHULMANCEO
Pete LeddyPete LeddyBoard Member
Barbara Hackman FranklinBarbara Hackman FranklinBoard Member

Similar to Pathway Genomics

VitaPath GeneticsVitaPath GeneticsFoster City, CA, USGenetic Testingest. 2009VitaPath GeneticsFoster City, CA, US · est. 2009

VitaPath Genetics, Inc. develops DNA tests to identify health risks and prevent serious diseases across the U.S.

Series C · $19.9M30
ColorColorBurlingame, CA, USGenetic Testing, Health Informationest. 2015ColorBurlingame, CA, US · est. 2015

Color: A health tech firm providing genetic tests for disease risk and medication response analysis.

Series E · $482M474
23andMe23andMeSunnyvale, CA, USGenetic Testingest. 200623andMeSunnyvale, CA, US · est. 2006

23andMe: A biotech firm offering direct-to-consumer genetic testing for ancestry and health predispositions.

Public · $1.1B816

People Similar to Jim Plante

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakHaeil YiHaeil YiCo-Founder · DunamuLee Sirg-OoLee Sirg-OoCEO · DunamuJeff ConlonJeff ConlonCo-Founder · EverspringMario VaronMario VaronCo-Founder · ImagineXJames FergusonJames FergusonCEO · ImmutableNandan PadukoneNandan PadukoneBoard Member · IM TherapeuticsRichard VlasimskyRichard VlasimskyBoard Member · ImidexTom GallagherTom GallagherCo-Founder · Miami International Holdings